Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection

NCT ID: NCT01844310

Last Updated: 2013-05-01

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 300 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2015-12-31

Brief Summary

This study is to evaluate the safety and efficacy of RAL-based regimen in treatment-experienced patients with resistant HIV infection

Detailed Description

In our study, both efficacy and safety of raltegravir(RAL)-based therapy will be assessed. 300 treatment-experienced patients with drug-resistant HIV will be randomized to two arms (2:1). Group A (n=200) will be assigned with RAL-based regimen (RAL+TDF+LPV/r).Group B (n=100) will be assigned with current second-line regimen in China (3TC+TDF+LPV/r). Both virological and immunological profiles and responses at baseline and at week 4, 8, 12, 24, 36, and 48 will be evaluated. This study will be the first large-scale, multicenter, randomized, prospective RAL-based therapy study in China for HIV/AIDs patients. The result will provide proves for further practical antiviral therapy for China or other resource-limiting countries.

Conditions

AIDS/HIV PROBLEM

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RAL +TDF+ LPV/r

Arm A: RAL +TDF+ KELETRA(LPV/r) Group A will be assigned with RAL+TDF+LPV/r.

Group Type: ACTIVE_COMPARATOR

RAL+TDF+LPV/r

Intervention Type: DRUG

Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).

3TC+ TDF+LPV/r

Arm B: 3TC+ TDF+KELETRA(LPV/r) Group B will be assigned with 3TC+TDF+LPV/r

Group Type: ACTIVE_COMPARATOR

3TC+TDF+LPV/r

Intervention Type: DRUG

Group B will be assigned with 3TC+TDF+LPV/r

Interventions

RAL+TDF+LPV/r

Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).

Intervention Type: DRUG

3TC+TDF+LPV/r

Group B will be assigned with 3TC+TDF+LPV/r

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age between 18-65 years

2. HIV seropositive and confirmed by western blot

3. have taken first line antiretroviral therapy for over one year and have any one of the criteria listed below (viral load of all the patients meeting these criteria should be confirmed at PUMCH laboratory)

1. Viral load more than 400 copies/ml

2. Viral rebound (confirmed by HIV RNA more than 400 copies/ml after virologic suppression)

3. When viral load cannot be monitored, patients experience immunologic failure who meet at least one of the criteria listed below will be enrolled:

• CD4 count equal to or lower than baseline level with first-line therapy,on two occasions over three months apart
• CD4 count with 50 percentage fall from the on-treatment peak value
• persistent CD4 count levels less than 100 cells/μl after over one-year antiretroviral therapy

Exclusion Criteria

• Previous use of protease inhibitors
• Previous use of integrase inhibitors
• Pregnancy and breastfeeding
• poor compliance and drug interaction,
• opportunistic infections or malignancy at recruitment; or opportunistic infections within three months but still unstable within 14 days prior to recruitment
• HBsAg positive
• patients with the any of the following test results during screening for inclusion: WBC count<2000/μl, neutrophil count<1000/μl, Hb<9g/dl, platelet count<75000/μl, serum creatinine>1.5 ULN, transaminases or alkaline phosphatase >3 ULN, total bilirubin>2 ULN, serum creatinine kinase>2 ULN
• CCr<60 ml/min
• Current intravenous drug use
• Severe neuropathy or mental disorder
• history of alcohol abuse and unable to withdrawal
• Severe peptic ulcer

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking Union Medical College

OTHER

Sponsor Role: lead

Responsible Party

LI Taisheng

director of the Department of Infectious Disease

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Peking Union Medical College Hospital

Beijing, , China

Countries

China

Central Contacts

Taisheng Li, MD

Role: CONTACT

litsh@263.net

86-10-69155086

Facility Contacts

Wei Lv, MD

Role: primary

lvweipumch@163.com

86-10-69155082

Other Identifiers

CACT1215-01

Identifier Type: -

Identifier Source: org_study_id